Evidence map›Paper›PMID 26362698›Full record

ReviewJournal of controlled release : official journal of the Controlled Release Society2015

Drug and gene delivery across the blood-brain barrier with focused ultrasound.

Kelsie F Timbie, Brian P Mead, Richard J Price

Abstract readReview
In one paragraph

Review in Journal of controlled release : official journal of the Controlled Release Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed, 2 pooled it
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

132 citing papers in PubMed, 2 syntheses or guidelines pooled it, 218 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Sonoselective Transfection of Glioma Endothelium.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Focused ultrasound therapy for neurological disease.Journal of medical ultrasonics (2001) · 2026
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

72 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Kelsie F TimbieDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA.
Brian P MeadDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA.
Richard J PriceDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA. Electronic address: rprice@virginia.edu.
University of Virginia · US

Funding

BASIC CARDIOVASCULAR RESEARCH TRAINING GRANTT32HL007284 · NHLBI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Brant E Isakson, Gary K Owens · 1985 to 2026
$19.6M
Brain Tumor-Penetrating Nanoparticle Delivery with MR-Guided Focused UltrasoundR01CA164789 · NCI · UNIVERSITY OF VIRGINIA · PI HANES, JUSTIN S., PRICE, RICHARD J. · 2012 to 2016
$3.1M
Immunotherapeutic Nanoparticle Delivery to Melanoma With MR-Guided Focused UltrasoundR01CA197111 · NCI · UNIVERSITY OF VIRGINIA · PI BULLOCK, TIMOTHY N, ENGELHARD, VICTOR H · 2015 to 2019
$2.6M
MRI-Guided miRNA Nanoparticle Delivery to Glioblastoma With Focused UltrasoundR01EB020147 · NIBIB · UNIVERSITY OF VIRGINIA · PI HANES, JUSTIN S., PRICE, RICHARD J. · 2015 to 2018
$2.4M
Bevacizumab Delivery to Glioblastoma with MR-Guided Focused UltrasoundR03EB016784 · NIBIB · UNIVERSITY OF VIRGINIA · PI PRICE, RICHARD J. · 2013 to 2014
$150k
NCI NIH HHS R01 CA164789NCI NIH HHS R01 CA197111NHLBI NIH HHS 5T32 HL007284NHLBI NIH HHS T32 HL007284NIBIB NIH HHS R01 EB020147NIBIB NIH HHS R03 EB016784
6 · The paper itself

Abstract

The blood-brain barrier (BBB) remains one of the most significant limitations to treatments of central nervous system (CNS) disorders including brain tumors, neurodegenerative diseases and psychiatric disorders. It is now well-established that focused ultrasound (FUS) in conjunction with contrast agent microbubbles may be used to non-invasively and temporarily disrupt the BBB, allowing localized delivery of systemically administered therapeutic agents as large as 100nm in size to the CNS. Importantly, recent technological advances now permit FUS application through the intact human skull, obviating the need for invasive and risky surgical procedures. When used in combination with magnetic resonance imaging, FUS may be applied precisely to pre-selected CNS targets. Indeed, FUS devices capable of sub-millimeter precision are currently in several clinical trials. FUS mediated BBB disruption has the potential to fundamentally change how CNS diseases are treated, unlocking potential for combinatorial treatments with nanotechnology, markedly increasing the efficacy of existing therapeutics that otherwise do not cross the BBB effectively, and permitting safe repeated treatments. This article comprehensively reviews recent studies on the targeted delivery of therapeutics into the CNS with FUS and offers perspectives on the future of this technology.

Indexed as

Drug Delivery SystemsGene Transfer TechniquesUltrasonic WavesAnimalsBlood-Brain BarrierHumansNanoparticlesPolymersPolymersBlood–brain barrierCNS drug deliveryFocused ultrasoundNanoparticles

Identifiers

PMID26362698
PMCPMC4656107
OpenAlexW1409374736

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.